DNMT3A and fatty liver disease: Along the course of our study, Kim et al showed that FGF19 ameliorates hepatic steatosis via DNMT3a‐mediated repression of lipogenesis.[33] The role of DNMT3A in this study appears to be contradictory to the inhibitory effect of DNMT3A on Klb and fatty oxidation we observed in our study.